Is IMUX or CTOR more profitable?

Citius Oncology's return on equity of -99.47% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Immunic N/A -220.75% -132.04% Citius Oncology N/A -99.47% -42.16%

Is CTOR or WHWK more profitable?

Whitehawk Therapeutics' return on equity of -79.63% beat Citius Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Citius Oncology N/A -99.47% -42.16% Whitehawk Therapeutics N/A -79.63% -74.01%

Does the media favor CTOR or WHWK?

In the previous week, Citius Oncology had 2 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 4 mentions for Citius Oncology and 2 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 1.45 beat Citius Oncology's score of 0.47 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Citius Oncology 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Whitehawk Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CTOR or IVVD more profitable?

Citius Oncology has a net margin of 0.00% compared to Invivyd's net margin of -138.90%. Invivyd's return on equity of -53.48% beat Citius Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Citius Oncology N/A -99.47% -42.16% Invivyd -138.90% -53.48% -41.56%

Does the media favor CTOR or IVVD?

In the previous week, Citius Oncology had 2 more articles in the media than Invivyd. MarketBeat recorded 4 mentions for Citius Oncology and 2 mentions for Invivyd. Invivyd's average media sentiment score of 0.94 beat Citius Oncology's score of 0.47 indicating that Invivyd is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Citius Oncology 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Invivyd 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CTOR or PRQR?

In the previous week, Citius Oncology and Citius Oncology both had 4 articles in the media. ProQR Therapeutics' average media sentiment score of 0.55 beat Citius Oncology's score of 0.47 indicating that ProQR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Citius Oncology 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ProQR Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Citius Oncology (CTOR) Competitors

$0.56 -0.02 (-2.77%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$0.56 +0.00 (+0.50%)

As of 07/24/2026 06:57 PM Eastern

Compare

CTOR vs. IMUX, DERM, WHWK, IVVD, and PRQR

Should you buy Citius Oncology stock or one of its competitors? MarketBeat compares Citius Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Citius Oncology include Immunic (IMUX), Journey Medical (DERM), Whitehawk Therapeutics (WHWK), Invivyd (IVVD), and ProQR Therapeutics (PRQR). These companies are all part of the "pharmaceutical products" industry.

How does Citius Oncology compare to Immunic?

Immunic (NASDAQ:IMUX) and Citius Oncology (NASDAQ:CTOR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

Citius Oncology has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A
Citius Oncology	$5.61M	9.32	-$24.76M	-$0.47	N/A

51.8% of Immunic shares are held by institutional investors. Comparatively, 70.5% of Citius Oncology shares are held by institutional investors. 5.5% of Immunic shares are held by insiders. Comparatively, 9.8% of Citius Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Immunic has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market. Comparatively, Citius Oncology has a beta of 3.47, indicating that its share price is 247% more volatile than the broader market.

In the previous week, Citius Oncology had 3 more articles in the media than Immunic. MarketBeat recorded 4 mentions for Citius Oncology and 1 mentions for Immunic. Immunic's average media sentiment score of 1.89 beat Citius Oncology's score of 0.47 indicating that Immunic is being referred to more favorably in the media.

Company	Overall Sentiment
Immunic	Very Positive
Citius Oncology	Neutral

Immunic presently has a consensus target price of $47.57, indicating a potential upside of 255.28%. Citius Oncology has a consensus target price of $6.00, indicating a potential upside of 967.24%. Given Citius Oncology's higher probable upside, analysts plainly believe Citius Oncology is more favorable than Immunic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Citius Oncology's return on equity of -99.47% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-220.75%	-132.04%
Citius Oncology	N/A	-99.47%	-42.16%

Summary

Citius Oncology beats Immunic on 11 of the 15 factors compared between the two stocks.

How does Citius Oncology compare to Journey Medical?

Citius Oncology (NASDAQ:CTOR) and Journey Medical (NASDAQ:DERM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

Citius Oncology has a net margin of 0.00% compared to Journey Medical's net margin of -14.82%. Journey Medical's return on equity of -35.57% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-99.47%	-42.16%
Journey Medical	-14.82%	-35.57%	-10.88%

70.5% of Citius Oncology shares are owned by institutional investors. Comparatively, 7.3% of Journey Medical shares are owned by institutional investors. 9.8% of Citius Oncology shares are owned by company insiders. Comparatively, 14.5% of Journey Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Citius Oncology has a beta of 3.47, meaning that its stock price is 247% more volatile than the broader market. Comparatively, Journey Medical has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market.

Journey Medical has higher revenue and earnings than Citius Oncology. Journey Medical is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Oncology	$5.61M	9.32	-$24.76M	-$0.47	N/A
Journey Medical	$61.86M	2.75	-$11.43M	-$0.37	N/A

Citius Oncology presently has a consensus price target of $6.00, indicating a potential upside of 967.24%. Journey Medical has a consensus price target of $13.00, indicating a potential upside of 110.02%. Given Citius Oncology's stronger consensus rating and higher probable upside, equities research analysts plainly believe Citius Oncology is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Citius Oncology had 3 more articles in the media than Journey Medical. MarketBeat recorded 4 mentions for Citius Oncology and 1 mentions for Journey Medical. Journey Medical's average media sentiment score of 1.89 beat Citius Oncology's score of 0.47 indicating that Journey Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Citius Oncology	Neutral
Journey Medical	Very Positive

Summary

Citius Oncology beats Journey Medical on 8 of the 15 factors compared between the two stocks.

How does Citius Oncology compare to Whitehawk Therapeutics?

Citius Oncology (NASDAQ:CTOR) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Whitehawk Therapeutics has lower revenue, but higher earnings than Citius Oncology. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Oncology	$5.61M	9.32	-$24.76M	-$0.47	N/A
Whitehawk Therapeutics	N/A	N/A	-$20.60M	-$1.68	N/A

Citius Oncology has a beta of 3.47, meaning that its share price is 247% more volatile than the broader market. Comparatively, Whitehawk Therapeutics has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market.

In the previous week, Citius Oncology had 2 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 4 mentions for Citius Oncology and 2 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 1.45 beat Citius Oncology's score of 0.47 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Citius Oncology	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Whitehawk Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Whitehawk Therapeutics' return on equity of -79.63% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-99.47%	-42.16%
Whitehawk Therapeutics	N/A	-79.63%	-74.01%

Citius Oncology currently has a consensus target price of $6.00, indicating a potential upside of 967.24%. Whitehawk Therapeutics has a consensus target price of $8.20, indicating a potential upside of 121.02%. Given Citius Oncology's higher possible upside, equities research analysts clearly believe Citius Oncology is more favorable than Whitehawk Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

70.5% of Citius Oncology shares are owned by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are owned by institutional investors. 9.8% of Citius Oncology shares are owned by insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Citius Oncology beats Whitehawk Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Citius Oncology compare to Invivyd?

Citius Oncology (NASDAQ:CTOR) and Invivyd (NASDAQ:IVVD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

Citius Oncology has higher earnings, but lower revenue than Invivyd. Invivyd is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Oncology	$5.61M	9.32	-$24.76M	-$0.47	N/A
Invivyd	$55.87M	3.22	-$52.49M	-$0.31	N/A

In the previous week, Citius Oncology had 2 more articles in the media than Invivyd. MarketBeat recorded 4 mentions for Citius Oncology and 2 mentions for Invivyd. Invivyd's average media sentiment score of 0.94 beat Citius Oncology's score of 0.47 indicating that Invivyd is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Citius Oncology	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Invivyd	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Citius Oncology has a beta of 3.47, meaning that its stock price is 247% more volatile than the broader market. Comparatively, Invivyd has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

Citius Oncology has a net margin of 0.00% compared to Invivyd's net margin of -138.90%. Invivyd's return on equity of -53.48% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-99.47%	-42.16%
Invivyd	-138.90%	-53.48%	-41.56%

70.5% of Citius Oncology shares are held by institutional investors. Comparatively, 70.4% of Invivyd shares are held by institutional investors. 9.8% of Citius Oncology shares are held by insiders. Comparatively, 12.3% of Invivyd shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Citius Oncology presently has a consensus target price of $6.00, suggesting a potential upside of 967.24%. Invivyd has a consensus target price of $8.00, suggesting a potential upside of 1,208.47%. Given Invivyd's higher possible upside, analysts clearly believe Invivyd is more favorable than Citius Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Invivyd beats Citius Oncology on 8 of the 15 factors compared between the two stocks.

How does Citius Oncology compare to ProQR Therapeutics?

Citius Oncology (NASDAQ:CTOR) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Citius Oncology has higher earnings, but lower revenue than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Oncology	$5.61M	9.32	-$24.76M	-$0.47	N/A
ProQR Therapeutics	$13.42M	13.50	-$47.73M	-$0.50	N/A

Citius Oncology has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -331.33%. ProQR Therapeutics' return on equity of -84.87% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-99.47%	-42.16%
ProQR Therapeutics	-331.33%	-84.87%	-37.78%

70.5% of Citius Oncology shares are owned by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are owned by institutional investors. 9.8% of Citius Oncology shares are owned by company insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Citius Oncology presently has a consensus target price of $6.00, indicating a potential upside of 967.24%. ProQR Therapeutics has a consensus target price of $7.33, indicating a potential upside of 326.36%. Given Citius Oncology's higher possible upside, analysts plainly believe Citius Oncology is more favorable than ProQR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Citius Oncology has a beta of 3.47, indicating that its share price is 247% more volatile than the broader market. Comparatively, ProQR Therapeutics has a beta of 0.04, indicating that its share price is 96% less volatile than the broader market.

In the previous week, Citius Oncology and Citius Oncology both had 4 articles in the media. ProQR Therapeutics' average media sentiment score of 0.55 beat Citius Oncology's score of 0.47 indicating that ProQR Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Citius Oncology	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ProQR Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Citius Oncology beats ProQR Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Citius Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTOR vs. The Competition

Export

Metric	Citius Oncology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$52.27M	$3.67B	$6.86B	$12.25B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-1.20	21.48	27.14	23.64
Price / Sales	9.32	169.92	517.01	89.03
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	1.04	7.88	10.28	6.07
Net Income	-$24.76M	$23.86M	$3.60B	$331.99M
7 Day Performance	-18.39%	-3.82%	-1.27%	-0.63%
1 Month Performance	-14.82%	-2.61%	-0.37%	-2.00%
1 Year Performance	-71.46%	32.79%	18.30%	13.62%

Citius Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTOR Citius Oncology	2.7239 of 5 stars	$0.56 -2.8%	$6.00 +967.2%	-71.2%	$52.27M	$5.61M	N/A	N/A	News Coverage Gap Up
IMUX Immunic	3.8623 of 5 stars	$14.72 -2.8%	$47.57 +223.2%	+25.1%	$199.00M	N/A	N/A	70	Positive News
DERM Journey Medical	2.5418 of 5 stars	$7.13 -2.4%	$13.00 +82.3%	-19.3%	$196.84M	$61.86M	N/A	90	Positive News
WHWK Whitehawk Therapeutics	2.452 of 5 stars	$3.92 +0.1%	$8.20 +109.5%	+91.2%	$193.89M	$7.14M	N/A	21	News Coverage Positive News
IVVD Invivyd	2.657 of 5 stars	$0.65 -4.1%	$8.00 +1,123.2%	-24.5%	$193.85M	$53.43M	N/A	100	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTOR) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Citius Oncology (CTOR) Competitors

CTOR vs. IMUX, DERM, WHWK, IVVD, and PRQR

How does Citius Oncology compare to Immunic?

Summary

How does Citius Oncology compare to Journey Medical?

Summary

How does Citius Oncology compare to Whitehawk Therapeutics?

Summary

How does Citius Oncology compare to Invivyd?

Summary

How does Citius Oncology compare to ProQR Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTOR vs. The Competition

Citius Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Citius Oncology (CTOR) Competitors

CTOR vs. IMUX, DERM, WHWK, IVVD, and PRQR

How does Citius Oncology compare to Immunic?

Which has stronger valuation & earnings, IMUX or CTOR?

Do insiders & institutionals have more ownership in IMUX or CTOR?

Which has more volatility & risk, IMUX or CTOR?

Does the media refer more to IMUX or CTOR?

Do analysts prefer IMUX or CTOR?

Is IMUX or CTOR more profitable?

Summary

How does Citius Oncology compare to Journey Medical?

Is CTOR or DERM more profitable?

Do insiders and institutionals believe in CTOR or DERM?

Which has more risk and volatility, CTOR or DERM?

Which has preferable earnings and valuation, CTOR or DERM?

Do analysts rate CTOR or DERM?

Does the media favor CTOR or DERM?

Summary

How does Citius Oncology compare to Whitehawk Therapeutics?

Which has better valuation and earnings, CTOR or WHWK?

Which has more risk & volatility, CTOR or WHWK?

Does the media favor CTOR or WHWK?

Is CTOR or WHWK more profitable?

Do analysts rate CTOR or WHWK?

Do institutionals & insiders believe in CTOR or WHWK?

Summary

How does Citius Oncology compare to Invivyd?

Which has higher valuation and earnings, CTOR or IVVD?

Does the media favor CTOR or IVVD?

Which has more risk and volatility, CTOR or IVVD?

Is CTOR or IVVD more profitable?

Do insiders and institutionals have more ownership in CTOR or IVVD?

Do analysts rate CTOR or IVVD?

Summary

How does Citius Oncology compare to ProQR Therapeutics?

Which has preferable earnings & valuation, CTOR or PRQR?

Is CTOR or PRQR more profitable?

Do insiders & institutionals believe in CTOR or PRQR?

Do analysts prefer CTOR or PRQR?

Which has more risk and volatility, CTOR or PRQR?

Does the media favor CTOR or PRQR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTOR vs. The Competition

Citius Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools